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Abstract: Lipid-based nanoparticles (NPs) with a small amount of surface-chelated nickel 
(Ni-NPs) were developed to easily formulate the human immunodeficiency virus (HIV) his-tagged 
Tat (his-Tat) protein, as well as to formulate and co-deliver two HIV antigens (his-p24 and 
his-Nef) on one particle. Female BALB/c mice were immunized by subcutaneous injection with 
his-Tat/Ni-NP formulation (1.5 µg his-Tat/mouse) and control formulations on day 0 and 14. 
The day 28 anti-Tat specific immunoglobulin G titer with his-Tat/Ni-NPs was significantly 
greater than that with Alum/his-Tat. Furthermore, splenocytes from his-Tat/Ni-NP-immunized 
mice secreted significantly higher IFN-γ than those from mice immunized with Alum/his-Tat. 
Although Ni-NPs did not show better adjuvant activity than Tat-coated anionic NPs made 
with sodium dodecyl sulfate (SDS/NPs), they were less toxic than SDS/NPs. The initial results 
indicated that co-immunization of mice using his-p24/his-Nef/Ni-NP induced greater antibody 
response compared to using Alum/his-p24/his-Nef. Co-delivery of two antigens using Ni-NPs 
also increased the immunogenicity of individual antigens compared to delivery of a single 
antigen by Ni-NPs. In conclusion, Ni-NPs are an efficient delivery system for HIV vaccines 
including both single antigen delivery and multiple antigen co-delivery.
Keywords: nanoparticle, nickel, HIV, antigen co-delivery, vaccine
Introduction
A protein-based vaccine can induce both antibody responses and T-cell responses 
including CTL cytotoxic T lymphocytes (CTL) in the immunized host. Furthermore, 
a protein contains multiple epitopes including T-helper (Th) epitopes, which play a 
key role in T-cell immunity, and potentiate CD8+ T-cell responses during priming 
and/or memory generation.1,2 The utility of adjuvants to enhance immune responses 
to protein-based vaccines is widely recognized.3,4 Specifically related to a potential 
human immunodeficiency virus (HIV) vaccine, it is critical to design and develop a 
vaccine that induces both neutralizing antibody and CTL activity, both of which have 
been shown to be essential for prevention and treatment of this disease.5,6
One direction of adjuvant design is to utilize particulate systems including 
liposomes,7,8 and other micro- and nanoparticles (NPs)9 to deliver antigens. Our labora-
tory has reported on the preparation of lipid-based NPs from oil-in-water microemulsion 
precursors and on the use of these NPs for enhancing immune responses to protein based 
vaccines.10,11 These NPs are approximately 100 nm in size and have the advantage of 
being prepared in a single step, one-vessel, process. It is also relatively easy to modify 
the physical characteristics of the particles by using appropriate charged surfactants. 
Moreover, the oil phase for preparation of these NPs is comprised of cetyl alcohol 
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and polysorbate 60, both of which are found in several 
pharmaceutical products and are biocompatible.12 In previ-
ous studies, the antigens were simply coated on oppositely 
charged (either cationic or anionic) nanoparticles wherein 
it is possible that some dissociation of the coated protein 
from the particle may occur in vivo, resulting in a decreased 
accumulation in antigen-presenting cells (APCs). In addition, 
the strong ionic surfactants for making the cationic or anionic 
NPs may be toxic to cells. To solve these problems, lipid 
NPs decorated with a small amount of accessible nickel on 
the surface were developed and this system led to enhanced 
immune responses.13 In these previous studies, the optimal 
binding of the his-tagged proteins (GFP or Gag p24) to 
Ni-NPs was about 1:33 w/w (protein-to-oil phase ratio) and 
was independent of the size and charge of the his-tagged 
protein. Apparently, the interaction between chelated nickel 
and the short sequence of histidine residues increased the 
delivery efficiency of the protein antigen to APCs.
Multivalent vaccines containing several antigens from 
different pathogens in one single formulation are commer-
cially available for vaccinating against diphtheria, tetanus, 
pertussis, polio, hepatitis B and Haemophilus influenzae 
type B.14,15 Multivalent vaccines not only have significant 
cost advantages but also have potential to induce synergistic 
effects between the antigens, since CD4 T helper epitopes in 
one antigen may enhance B- and T-cell responses induced 
by other antigens.2 Thus, ideally, a viable vaccine delivery 
system should be able to deliver multiple antigens. Recently, 
Lamalle-Bernard and colleagues developed multivalent 
vaccines based on anionic polylactic acid (PLA) NPs 
for co-delivery of HIV p24 and gp120 proteins and they 
showed that the NPs preserved antigenicity and immunoge-
nicity of p24 and gp120.16
The HIV gag gene encodes for four major Gag proteins 
in the mature virus.17 Gag proteins are currently under 
investigation as potential candidates for the HIV vaccines. 
Of these four proteins, the Gag p24 protein has been shown 
to be the most conserved among the different HIV subtypes 
and many groups have also identified Gag p24 as the target 
of Gag-specific cellular responses.18,19 More importantly, 
a recent study of HIV-infected patients highlighted the 
significance of strong Gag p24-specific cellular responses 
in controlling viral replication and CD4+ T cell counts.20 
Thus, these features make the HIV-1 Gag p24 protein an 
attractive and relevant choice for inclusion in a multivalent 
HIV vaccine.
HIV-1 Nef is an early-expressed regulatory protein which 
plays an important role in CD4 and major histocompatibility 
complex (MHC) class I downregulation, the stimulation of 
virus infectivity and the alteration of the activation state of 
cells.21 Moreover, Nef is essential for the maintenance of high 
levels of viral replication and acquired immunodeficiency 
syndrome (AIDS) pathogenesis in simian immunodefi-
ciency virus (SIV)-infected macaques and has also been 
shown to influence progression to AIDS in HIV-infected 
individuals.22,23 These in vitro and in vivo observations sug-
gest that Nef represents another possible attractive target for 
the development of a multivalent therapeutic HIV vaccine.
However, p24 and Nef proteins have negative and posi-
tive charges, respectively, under physiological pH (pH 7.4) 
precluding the use of either cationic or anionic NPs to bind 
these two proteins together on the same particle. As an 
alternative, Ni-NPs have roughly equal binding affinity to 
his-tag proteins having similar sizes. Since both his-p24 
and his-Nef have molecular weights of around 25–27 kDa, 
they have the potential to be formulated in Ni-NPs and 
co-delivered to dendritic cells.
HIV-1 Tat protein is an RNA binding transcriptional regula-
tory protein expressed early in HIV-1 infection, and necessary 
for high level expression of viral proteins.10,11 Tat shows very 
little variability and is highly conserved in the first exon among 
the different subtypes, with the exception of the O subtype.24,25 
Neutralization of Tat might prevent the transactivation of other 
infected cells, and also prevent the neurotoxic properties. In 
previous studies by our group, negatively-charged nanoparticles 
were utilized to coat the positively-charged Tat (1–72 aa) on 
the surface of the nanoparticles by charge interaction. Sur-
face coated Tat (1–72 aa) led to significant enhancements in 
antibody titer, Tat-neutralizing antibodies, and inhibition of 
Tat-mediated long terminal repeat (LTR) transactivation versus 
Alum-adjuvanted Tat.26 In addition, the nanoparticle vaccine 
delivery system was shown to be dose-sparing.
In order to further investigate the utility of Ni-NPs for 
vaccine formulation, we have extended previous studies of 
Ni-NPs to include his-Tat antigen. In addition, we have com-
pared the adjuvant activity and toxicity of Ni-NPs with the 
previous reported ionic SDS/NPs. Finally, the co-delivery of 
multiple antigens, p24 and Nef, using this platform vaccine 
delivery system was also studied.
Materials and methods
Materials
Emulsifying wax (E-wax), comprised of  cetyl alcohol and 
polysorbate 60 in a molar ratio of 20:1, and aluminum hydroxide 
were purchased from Spectrum (New Brunswick, NJ). PBS/
Tween 20 buffer, horseradish peroxidase (HRP), cetyltrimethyl 
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ammonium bromide (CTAB), SDS and mannitol were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Alum 
was purchased from Spectrum Chemicals and Laboratory 
Products (Gardena, CA). Brij 78 was purchased from 
Uniqema (New Castle, DE). 1,2-Dioleoyl-sn-Glycero-3-
[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] 
nickel and ammonium salt, abbreviated DOGS-NTA-Ni and 
DOGS-NTA, respectively, were purchased from Avanti 
Polar Lipids (Alabaster, AL). Goat anti-mouse immuno-
globulin G (IgG) and peroxidase-linked species specific 
F(ab′)
2
 fragment was purchased from Amersham Pharmacia 
Biotech (Piscataway, NJ). Interferon-γ (IFN-γ) ELISA kit, 
streptavidin horseradish peroxidase (Sv-HRP), fluorescein 
isothiocyanate (FITC)-labeled anti-mouse CD11c antibody 
and biotinylated rat anti-mouse IgG1 and IgG2a monoclonal 
antibodies were from BD Biosciences Pharmingen (San 
Diego, CA). Tetramethylbenzidine (TMB) Substrate Kit and 
NHS-fluorescein were purchased from Pierce (Rockford, 
IL). The antigens his-p24 (a.a. 133–363) and his-Nef (a.a. 
3–190) were obtained from Bioclone Inc (San Diego, 
CA) with purity of 90% by SDS-Page. NHS-fluorescein 
and Zeba de-salting column were purchased from Pierce 
Biotechnology (Rockford, IL).
expression of his-Tat
Tat 1–72 cDNA was polymerase chain reaction (PCR) 
amplified from HIV-1 strain HXB2 (from NIH AIDS 
reagent repository), using primers 5′-TAGGATCCGC-
CACCATGGAGCCAGTAGATC-3′  (forward) and 
5′-GCGAATTCTCATTGCTTTGATAGAGAAAC-3′ 
(backward), and inserted into pHAT10 vector (BD Biosci-
ences, San Jose, CA) at BamH I/EcoR I sites. The sequence 
containing both his-tag Tat and Tat was then PCR ampli-
fied for two rounds from the resulting pHAT-Tat plasmid 
using primers 5′-CTGTTCCAGGGGCCCTTGAAGGAT-
CATCTC-3′ (forward, for first round PCR), 5′-AGAATTCT-
GGAAGTTCTGTTCCAGGGGCCC-3′ (forward, for 
second round PCR), and 5′-ACTCGAGTCATTGCTTT-
GATAGAGAAAC-3′ (backward, for both), and inserted 
into pGEM-4T2 vector (GE Healthcare, Piscataway, NJ) at 
EcoR I/Xho I sites. A new cleavage site for PreScission Pro-
tease (GE Healthcare) was also incorporated between GST 
and his-tag sequence. The resulting pGET-his-Tat plasmid 
was transformed into BL21-T1 competent cells. Expression 
of the fusion protein was induced with 3 mM IPTG for four 
hours. Cells were then harvested and extracted with lysis 
buffer (1 × phosphate-buffered saline [PBS] with 100 µM 
phenylmethanesulphonylfluoride [PMSF]). For his-tag Tat 
protein, the clarified cell extract was applied to a 5 ml GSTrap 
Sepharose column (GE Healthcare). The column was washed 
with 10 column volumes of PBS. The fusion protein bound 
on the column was then digested with 80 units of PreScission 
Protease overnight at 4 °C. His-tag Tat protein released from 
the column by digestion was then collected and analyzed 
by SDS-PAGE and western blot. The eluted fractions were 
separated by 12.5% SDS-PAGE gel and immunoblotted with 
anti-Tat antibody. The immunoreactive bands showed the 
monomer (∼10 kDa) as well as multimers of Tat. Coomassie 
bright blue (CBB) staining showed a similar pattern of protein 
bands as the western blot.
Preparation of ni-nPs and nTA-nPs
Ni-NPs were prepared as described previously with 
slight modifications.13 Briefly, in a 7 ml glass vial, 4 mg 
of emulsifying wax (the oil phase) and 7 mg (3 mM) of 
Brij 78 (the surfactant) were added and then melted at 
65 °C. To this vial, 21.2 µl (0.1 mM) of DOGS-NTA-Ni 
(10 mg/ml stock in chloroform) was added and the chloro-
form was evaporated on a hot plate (65 °C) while stirring. 
De-ionized, 0.2 micron-filtered water (100 µl) was added to 
the vial at 65 °C and the contents of the vial were mixed on 
the hot plate for 2 min to form a slurry-like mixture. Then, 
1.9 ml water was added to the mixture at 65 °C to form clear 
oil-in-water microemulsions. NPs were obtained by cooling 
the vials to room temperature while stirring. NPs of simi-
lar composition but without Ni were prepared in the same 
manner using 0.1 mM of DOGS-NTA lipid instead, referred 
to as NTA-NPs. Excess DOGS-NTA-Ni or DOGS-NTA 
was separated from the Ni-NPs by using a gravity packed 
Sepharose CL4B gel permeation chromatography (GPC) 
column (15 × 70 mm). Briefly, 200 µl of the Ni-NPs was 
passed down the GPC column using PBS, pH 7.4 as the 
mobile phase. Fractions (1 ml) were collected and the 
fractions containing the NPs (as determined by measuring 
the particle size intensity with the particle sizer) were stored 
at 4 °C for further in vivo and in vitro study. The NPs were 
characterized by measuring their size, using a Coulter N5 
Submicron Particle Sizer (Coulter Corporation, Miami, FL) 
at 90°, and charge, using a Malvern Zeta Sizer 2000 (Malvern 
Instruments, Southborough, MA).
Preparation of fluorescence-labeled 
his-tag Tat protein (fluo-his-Tat) 
and binding of fluo-his-Tat to Ni-NPs
Fluo-his-Tat was prepared using NHS-fluorescein, which 
is an amine-reactive derivative of fluorescein dye. Briefly, 
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NHS-fluorescein (1 mg) was dissolved in 1000 µl DMSO, 
and 13 µl of this solution was added to 300 µg his-Tat protein 
dissolved in 300 µl PBS buffer. The reaction was performed 
at room temperature for one hour in the dark. Unreacted 
NHS-fluorescein was removed using a Zeba de-salting 
column. The degree of modification was calculated using the 
fluorescein molar extinction coefficient = 68,000 M-1 cm-1 
and the method provided by the vendor. Fluo-his-Tat was 
stored at -80 °C until use. To determine the optimal binding 
ratios, fluo-his-Tat was mixed with the GPC column-purified 
Ni-NPs at a 1:20, 30, 40, 50, 60 w/w ratios in PBS, pH 7.4 
at 4 °C overnight. Free protein was separated from NP 
bound protein by passing the fluo-his-Tat and NP mixtures 
through the Sepharose CL4B column using PBS, pH 7.4 as 
the mobile phase. Fractions collected (1 ml) were analyzed 
by fluorescence to determine the percent of his-Tat bound 
to Ni-NPs.
Preparation of anionic SDS/nPs 
and cationic CTAB/nPs
Cationic and anionic NPs from oil-in-water microemulsion 
precursors were prepared as previously described with 
slight modification.10,11 Briefly, 2 mg of emulsifying 
wax and 3.5 mg of Brij 78 was melted and mixed 
at ∼65 °C. Deionized water (980 µl) was added to the 
melted wax and surfactant while stirring to form an 
opaque suspension. Finally, 20 µl of CTAB (50 mM) or 
SDS (50 mM) was added to form clear microemulsions 
at 60–65 °C. The microemulsions were cooled to room 
temperature while stirring to obtain NPs (2 mg/ml). The 
final concentration of components in the NP suspension 
was E-wax (2 mg/ml), Brij 78 (3 mM), and either 1 mM 
SDS (for anionic SDS/NPs) or 1 mM CTAB (for cationic 
CTAB/NPs).
Mouse immunization study  
using his-Tat/ni-nP
Female BALB/c mice (8–10 weeks old) obtained from 
Charles River Laboratories (Indianapolis, IN) were immu-
nized subcutaneously with 150 µl of the formulations. 
Mice (n = 8/group) were dosed on day 0 and day 14 with 
his-Tat/Ni-NP, his-Tat/NTA-NP, his-Tat/SDS/NP, or his-Tat 
adjuvanted with Alum. The Tat doses in every group were 
kept as 1.5 µg per mouse and E-wax for preparation of NP 
or Alum was kept as 100 µg. On day 28, mice were bled by 
cardiac puncture and sera were separated. All sera collected 
were stored at -20 °C for further characterization.
Determination of anti-Tat, p24  
and nef antibody titers
Antigen-(Tat, p24 or Nef) specific serum IgG, IgG1 and 
IgG2a antibody titers were determined by ELISA. Briefly, 
96-well plates (Costar) were coated with 100 µl of recombi-
nant Tat, his-p24 or his-Nef (10 µg/ml in 0.01 M carbonate 
buffer, pH 9.6) overnight at 4 °C. The plates were blocked 
for one hour at 37 °C with 200 µl of 2% BSA prepared 
in PBS/Tween 20. The plates were then incubated with 
100 µl per well of mouse serum diluted appropriately in 
2% BSA/PBS/Tween 20 for two hours at 37 °C. The plates 
were washed with PBS/Tween 20 and incubated with 
100 µl/well sheep-anti-mouse IgG HRP (1:5000 in 2% 
BSA/PBS/Tween 20) for one hour at 37 °C. For IgG1 and 
IgG2a determination, the plates were similarly incubated with 
goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP 
diluted 1:5000 (2% BSA/PBS/Tween 20). After washing the 
plates with PBS/Tween 20, plates were developed by adding 
80 µl of TMB substrate and incubating for 10 min at RT. The 
color development was stopped by the addition of 50 µl of 
2M H
2
SO
4
 and the OD at 450 nm was read using a Bio-Tek 
Synergy 2 Microplate Reader (Bio-Tek Instruments, Inc.). 
The endpoint titer was defined as the highest reciprocal dilu-
tion of sera yielding an OD
450
 value at least 3 × background 
obtained using samples obtained from naïve mice.
Cytokine release assay  
from Tat stimulated splenocytes
Mice were sacrificed on day 28 and spleen cells were isolated. 
Red blood cells were lysed by adding 1 × ammonium 
chloride/potassium carbonate (ACK) buffer (156 mM 
NH
4
Cl, 10 mM KHCO
3
 and 100 µM EDTA) and incubating 
for 1–2 min at RT. The cells were spun down at 1,500 rpm, 
4 °C for 10 min. The cells were resuspended in RPMI 1640 
(supplemented with 10% heat-inactivated fetal calf serum, 
1 mM HEPES, 2 µM l-glutamine, 10 U/ml penicillin, 
100 U/ml streptomycin, 50 µM 2-mercaptoethanol). 
To measure cytokine release from stimulated splenocytes, 
parallel 48-well plates were set up using 1 × 106 cells/well 
(total volume of 400 µl) and incubated with media alone or 
Tat (5 µg/ml) at 37 °C, 5% CO
2
 for 72 hours. The superna-
tants were collected at 72 hours and stored at -80 °C for 
IFN-γ analysis by ELISA (BD Biosciences).
nP toxicity to dendritic cells
DC2.4 cells were obtained from bone marrow cells infected 
with a retrovirus encoding myc and raf  by using supernatant 
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from NIH J2 Leuk cells, as previously described.27 DC2.4 
cells were provided by Dr. Leaf Huang at the University of 
North Carolina at Chapel Hill. After incubation of DC2.4 
cells with NPs, the cells were stained with CD11c and prop-
idium iodide and analyzed by flow cytometry. The percentage 
of cell death of DC was determined by the proportion of 
PI+ cells within the CD11c+ region using a BD FACSCanto 
digital flow cytometer (BD Biosciences).
Preparation of his-p24/his-nef/ni-nP 
formulation and in vivo immunization 
study
Ni-NPs were prepared as described above. Since the molecu-
lar weights of p24 and Nef are similar (about 24–27 kDa), the 
previous published optimal P : L weight ratio (1:33.3 w/w) for 
his-p24 was used for preparation of the formulation his-p24/
his-Nef /Ni-NPs.13 Briefly, his-p24 and his-Nef were bound 
to Ni-NPs at the weight ratio of 1.5:1.5:100 (his-p24:his-Nef:
Ni-NPs) in PBS at 4 °C overnight. The same weight ratio 
of proteins to Alum was used to prepare the Alum/his-p24/
his-Nef formulation. Single antigen formulations his-p24/
Ni-NP and his-Nef/Ni-NP were prepared at the weight ratio 
of 1:33.3 w/w. Blank NPs without DOGS-NTA-Ni were 
added to the his-p24/Ni-NP and his-Nef/Ni-NP to retain 
the same amount of NPs among all the formulations. Female 
BALB/c mice (8–10 weeks old) were immunized subcutane-
ously with 150 µl of the formulations. Mice (n = 8/group) 
were dosed on day 0 and day14 with 1.5 µg his-p24 and/or 
his-Nef per mouse. The mice were bled by cardiac puncture 
on day 28 and the sera were separated and stored at -20 °C 
for antigen-specific IgG analysis by ELISA.
Statistical analysis
The data were analyzed using Prism 3.0 (GraphPad Software, 
La Jolla, CA). A one-way ANOVA analysis was performed 
first followed by the Tukey’s test for multiple comparisons. 
Data were concluded to be statistically different if p  0.05.
Results and discussion
Optimization and characterization 
of his-Tat/ni-nP formulations using 
fluorescent labeled his-Tat
We reported previously on the use of lipid-based NPs with 
a small amount of Ni-NPs to deliver his-p24 antigen.13 
To test if this system is suitable to deliver other HIV anti-
gens such as cationic Tat, his-Tat was bound to the surface 
of Ni-NPs. Fluorescent-labeled his-Tat was prepared and 
used to optimize and characterize the formulation. To avoid 
the over-modification of his-Tat by fluorescein, a 1:1 molar 
ratio of protein to NHS-fluorescein was used in the labeling 
reaction. This reaction yielded fluorescein-his-Tat with a 
degree of modification of ∼10%.
The elution profile of fluorescein-labeled his-Tat mixed 
with Ni-NPs at five different weight ratios is shown in 
Figure 1. NPs eluting in fractions 3–6 were monitored by 
light-scattering intensity (not shown) and free protein was 
detected in fractions 8–12 and quantified by fluorescence 
intensity (y-axis). The broadening of the peaks in fractions 
3–6 with increasing his-Tat/Ni-NP ratios correspond directly 
to the amount of Ni-NPs that were loaded onto the column. 
At a 1:60 w/w ratio of his-Tat to Ni-NPs (P:L), the fluores-
cence intensity of free his-Tat (fraction 10) was very low 
while the NP bound his-Tat (fraction 4) was the highest, 
suggesting the majority of the protein was associated with 
NP at this ratio. The his-Tat binding to Ni-NPs was found 
to be stable for four hours in PBS at 37 °C, pH 7.4 with less 
than 10% of the protein released and particle sizes retained at 
approximately 120 nm over the time frame (data not shown). 
Therefore, the ratio of P:L close to 1:60 (w/w) was used 
for the in vivo studies. The optimal P:L ratio for his-Tat is 
different from a previous report of his-p24.13
In vivo immunization using optimized 
his-Tat/ni-nP formulations
Based on the optimization studies assessing the fluorescence 
labeled his-Tat binding to Ni-NPs study, his-Tat was bound 
to Ni-NPs at a 1:60 w/w ratio for the in vivo immuniza-
tion studies. The binding of his-Tat to the Ni-NPs was also 
confirmed by SDS-PAGE (data not shown). The use of 
DOGS-NTA entrapped in NPs was also investigated to con-
trol for non-specific adsorption of the protein on the surface 
of the NPs. The carboxylic groups of the NTA provide an 
overall slightly net-negative charge to the surface of the NPs 
and could allow his-Tat, a cationic protein, to be coated on 
the surface of the particles. The strong negatively-charged 
NPs made using SDS as a surfactant was used as a positive 
control.11 As shown in Figure 2A, the Ni-NPs resulted in 
significant enhancement in antibody responses compared 
to both Alum and NTA-NPs (p  0.05). However, the total 
Tat-specific IgG titer for the Ni-NPs and SDS/NPs was 
comparable. In this study, the primary binding of protein on 
NPs is mediated through the interaction of the N-terminal 
his-tag to Ni on the surface of NPs. Therefore, it is possible 
that this binding may lead to an orientation of the protein 
that is different than when the same protein is adsorbed 
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onto SDS-NPs or adjuvanted with Alum thereby resulting 
in qualitative differences in the induced immune responses. 
In fact, in previous studies we have shown by epitope map-
ping that Tat adsorbed on SDS-NPs led to differences in 
immune responses to several different peptide regions on 
Tat as compared to Tat adjuvanted with Alum.10
It is known that during an immune response, the release of 
Th1 or Th2 cytokines will affect the production of antibody 
isotypes. Th1 cytokines like IFN-γ promote class switching 
to the IgG2a isotype. BALB/c mice bias the immune response 
towards a Th2 profile, resulting in a relative lack of IFN-γ and 
more antibodies of IgG1 isotype. The serum isotype levels, 
IgG1 versus IgG2a, were measured to assess the type of 
immune response generated (ie, Th1 or Th2). The isotype 
analysis in these studies revealed that the Ni-NPs resulted 
in higher levels of IgG2a compared to the Alum group 
(p  0.01), while the IgG1 levels were comparable to the 
other three immunized groups (Figure 2B). The data indi-
cated that all the NP groups (Ni-NP, NTA-NP and SDS/NP) 
showed a balanced IgG2a/IgG1 ratio of approximately 0.5. 
In contrast, the IgG2a/IgG1 ratio in the Alum group was 
0.153 indicating a more Th2-biased response.
The cellular immune responses in these studies were 
evaluated by IFN-γ release assays. Splenocytes from immu-
nized mice that were stimulated in vitro with recombinant 
Tat protein demonstrated significantly higher IFN-γ release 
than those from naive mice. Moreover, the IFN-γ release 
from stimulated splenocytes of Ni-NP immunized mice was 
significantly higher than that from the Alum and NTA-NPs 
groups (Figure 3). Although Ni-NPs showed superior adju-
vant activity than Alum and NTA-NPs, it had comparable 
activity with the previously developed SDS/NPs. Thus, 
although the different NP types induced similar Th1/Th2 
profiles inferred by antibody isotype differences, Ni-NP 
and SDS/NP induced a higher Th1 response inferred by 
IFN-γ release from spleen cells. This may reflect a greater 
stimulation of CD8 T cells by the Ni-NPs and SDS/NP 
which might not contribute to antibody isotype switching 
in vivo.
Dendritic cell toxicity induced by nPs
The immunization results above showed that the Ni-NP 
vaccine delivery system was suitable for his-Tat delivery 
and generated enhanced immune responses versus Alum 
adjuvant, but comparable to that of the previously devel-
oped SDS/NPs. However, we have previously noted that 
the highly anionic SDS NPs showed a dose-dependent toxic 
effect on bone marrow-derived macrophages (Woodward 
and Mumper, unpublished results). To ascertain potential 
differences in the toxicity of the various NPs used in 
these studies, the toxicity of Ni-NPs, NTA-NPs, SDS/NPs 
(anionic) and CTAB/NPs (cationic) were investigated 
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Figure  Binding of fluo-his-Tat to Ni-NPs. The GPC purification profile for fluo-his-Tat bound to Ni-NPs at 1:20, 30, 40, 50, 60 w/w ratio of protein to Ni-NPs. Ni-NPs eluted 
in fraction 3–6 as determined by particle size intensity (not shown). The extent of his-Tat bound to Ni-NPs was determined by separating Ni-NP bound protein (fractions 3–6) 
from free protein, which elutes in faction 8–12 as determined by fluorescence intensity measurements.
Abbreviations: gPC, gel permeation chromatography; nPs, nanoparticles.
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Figure  Tat-specific serum IgG titer. BALB/c mice were immunized on day 0 and day 14 with 150 µl of each formulation containing 1.5 µg his-Tat and 100 µg nPs or Alum. 
(A) Tat-specific total serum IgG titers were evaluated on Day 28 by ELISA. Data represent the mean ± S.D. *p  0.05 compared to nTA and Alum groups. (B) Tat-specific 
serum Igg2a and Igg1 titer were evaluated on day 28 by eLISA.  The mean Igg2a/Igg1 ratio is indicated on the bottom of the graphed titer for each group. Data represent 
the mean ± S.D. **p  0.01 compared to Alum group.
Abbreviations: Igg, immunoglobulin g; nTA, nitrilotriacetic acid; nPs, nanoparticles.
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in the DC2.4 dendritic cell line. All the formulations 
showed low toxicity for 24-hour treatment (around 5% 
PI-positive cells). However, after 48-hour treatment, the 
charged NP (SDS/NPs and CTAB/NPs)-treated DC2.4 
cells showed more than 20% PI-positive (dead) cells. Both 
NTA-NPs and Ni-NPs showed less toxicity than either 
of the charged NPs (p  0.05 compared to SDS/NPs, 
p  0.01 compared to CTAB/NPs) (Figure 4). The data also 
showed that positive charged CTAB/NPs were more toxic 
than negative-charged SDS/NPs (p  0.05) (Figure 4). 
Thus, Ni-NPs may be superior to charged NP in terms of 
safety/toxicity.
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Figure  Cellular responses to his-Tat. Mice were immunized with 1.5 µg of his-Tat on day 0 and day 14. Spleens were harvested and pooled for each group on day 28. Cells 
(1 × 106) were stimulated with recombinant Tat (5 µg/ml) and the supernatants were evaluated for IFN-γ release at 72 h by eLISA.  The data represent the mean ± SD (n = 3). 
*p  0.05 compared to the Alum and nTA groups.
Abbreviations: nTA, nitrilotriacetic acid; nPs, nanoparticle; IFn-γ , interferon-γ ; SD, standard deviation; SDS, sodium dodecyl sulfate.
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Figure  Cytotoxicity induced by nPs in DC2.4 cells.  DC2.4 cells were incubated with nPs (11 µg/ml) for the indicated time.  The cells were washed and incubated with FITC 
labeled CD11c and PI.  The percentage of cell death was determined by the proportion of PI+ cells within the CD11c+ region.  The data represent the mean ± SD (n = 5).
Notes: *p  0.05 compared to nTA-nPs, ni-nPs and CTAB-nPs; **p  0.01 compared to nTA-nPs and ni-nPs.
Abbreviations: PI, propidium iodine; CTAB, cetyltrimethyl ammonium bromide; NPs, nanoparticles; FITC, fluorescein isothiocyanate.
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ni-nPs for the delivery  
of multiple antigens
Although negatively-charged SDS/NPs are suitable for the 
delivery of Tat and other cationic antigens, they are obviously 
not suitable for multiple antigens especially if the antigens are 
negatively-charged. The toxicity study in DC2.4 cells also 
showed that the charged NP may not be warranted for larger 
antigen doses. An alternative strategy would be to utilize 
Ni-NPs to bind various his-tagged proteins irrespective of their 
native charge. To test this hypothesis, the his-tagged antigens, 
gag p24 and Nef, were bound to Ni-NPs. Indeed, mice 
co-immunized with his-p24 and his-Nef antigens co-bound 
to Ni-NPs, had higher p24-specific antibodies as compared 
to mice immunized with p24-alone bound to NPs (p  0.05). 
In addition, his-p24/his-Nef/Ni-NP resulted in significant 
enhancement in p24-specific antibody response compared to 
his-p24/his-Nef adjuvanted with Alum (p  0.05) (Figure 5A). 
In a similar manner, mice immunized with his-p24/his-Nef/
Ni-NP had greater Nef-specific antibodies than mice immu-
nized with Nef alone bound to NPs (Figure 5B). Thus, Ni-NPs 
provide a distinct advantage of allowing the binding of varied 
his-tagged proteins, regardless of charge.
In these current studies, Ni-NPs were successfully 
used for the delivery of cationic his-Tat antigen to induce 
enhanced immune responses compared to Alum. Although 
this system did not show superior adjuvant activity compared 
*
*
*
100×
1000×
10000×
100×
1000×
10000×
4
3
2
1
0
3.5
2.5
1.5
0.5
3
2
1
0
3.5
2.5
1.5
0.5
Ni-NPs/p24/Nef
Ni-NPs/p24/Nef
Ni-NPs/p24
Ni-NPs/Nef
Naive
Naive
Alum with p24/Nef
Alum with p24/Nef
A
B
G
ag
 p
24
-s
pe
ci
fic
 s
er
um
 Ig
G
O
D
 @
 4
50
 n
m
N
ef
-s
pe
ci
fic
 s
er
um
 Ig
G
O
D
 @
 4
50
 n
m
Figure  ni-nPs for co-delivery of his-tagged p24 and nef antigens. BALB/c mice were immunized on day 0 and day 14 with 150 µl of each formulation containing 1.5 µg 
his-p24 and/or 1.5 µg his-nef adjuvanted by 100 µg nPs or Alum.  Total serum Igg levels at day 28 were diluted 100, 1,000 and 10,000-fold and measured by eLISA. A) Gag 
p24-specific serum IgG titer. *p  0.05 compared to Alum/his-p24/his-nef and his-p24/ni-nP groups. B) Nef-specific serum IgG titer, *p  0.05 compared to his-nef/ni-nP 
group. Data represent the mean ± SD.
Abbreviations: Igg, immunoglobulin g; nPs, nanoparticles; SD, standard deviation.
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to SDS/NPs, it showed less toxicity to dendritic cells than 
SDS/NPs. Interestingly, cationic CTAB/NPs were more 
toxic to dendritic cells than anionic SDS/NPs. Dendritic 
cells play a central role to link the innate immune responses 
to adaptive immune responses, so their life-span affects the 
potency of vaccines. For example, it was reported that a 
high dose of cationic liposome induced apoptosis of den-
dritic cells leading to compromised immune responses.28 
In addition, two other reports showed that the potency of a 
dendritic cell-based vaccine was enhanced by incorporating 
anti-apoptotic strategies for prolonging dendritic cell life.29,30 
Therefore, utilizing less toxic but equally effective vaccine 
carriers such as Ni-NPs to bind his-tagged protein antigens 
have potential advantages.
Conclusions
We have expanded our studies of Ni-NPs as an effective 
vaccine delivery vehicle to include the delivery of cationic 
his-Tat antigen, and the co-delivery of gag p24 and Nef. 
Ni-NPs induced enhanced Tat-specific immune responses 
compared to Alum. Although this system did not show supe-
rior adjuvant activity compared to SDS/NPs, it showed less 
toxicity to dendritic cells than SDS/NPs. Ni-NPs were found to 
be suitable for the co-delivery of p24 and Nef protein antigens, 
and the binding of various his-tagged antigens on the same 
particle is regardless of the charge. The safety and adjuvant 
activity of Ni-NPs make this system suitable for HIV vaccine 
development, especially for multivalent vaccines.
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